Testing Two 'Sleep Peptides' in Rats: Neither DSIP nor AVT Actually Promoted Sleep

Rats received DSIP via systemic injection (intraperitoneal) or direct brain ventricle infusion at multiple doses. AVT was administered into brain ventricles at extremely low concentrations. Motor activity was monitored over 24 hours, and sleep architecture was assessed using EEG recordings, with particular attention to delta-band power (the signature of deep slow-wave sleep).

DSIP was originally isolated and named for its apparent ability to induce slow-wave sleep, and it became widely referenced in the peptide supplement community. This early negative study is important because it challenged the foundational claim about DSIP's sleep-promoting properties using rigorous EEG and behavioral methods. It helped establish that DSIP's effects are more complex and less specific than its name implies.

This 1980 study is part of a broader story about how peptides discovered in the mid-20th century were often named for their initial observed effects before those effects were fully validated. DSIP remains commercially available as a supplement despite decades of inconsistent sleep data. The study also highlighted AVT's remarkable potency at femtomolar doses, contributing to ongoing research into ultra-low-dose neuropeptide signaling. The search for genuine sleep-promoting peptides has since shifted to other candidates like orexin antagonists.

This was a rat study, and sleep architecture differs significantly between rodents and humans. The sample size was not reported in the abstract. DSIP's effects on sleep may be species-specific or require specific conditions not replicated in this experimental setup. The study tested a limited range of doses and timing protocols — it's possible that different regimens might produce different results.